NCT03379558View on ClinicalTrials.gov

Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

TerminatedOBSERVATIONAL

Enrollment

37

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

September 4, 2020

Study Completion Date

September 4, 2020

Conditions

Hypercholesterolemia

Interventions

DRUG

ALIROCUMAB SAR236553 (REGN727)

Pharmaceutical form:as per routine practice Route of administration: subcutaneous

Trial Locations (1)

00000

Investigational site UNITED STATES, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY